OPKO Health (OPK) – Investment Analysts’ Weekly Ratings Changes

Several analysts have recently updated their ratings and price targets for OPKO Health (NASDAQ: OPK):

• 10/16/2026 – OPKO Health was given a new $4.00 price target by UBS Group.
• 10/16/2026 – OPKO Health had its “buy” rating reaffirmed by UBS Group.
• 10/16/2026 – OPKO Health had its “buy” rating reaffirmed by HC Wainwright.
• 10/16/2026 – OPKO Health had its “overweight” rating reaffirmed by Piper Sandler. They now have a $4.00 price target on the stock, up from $3.00.
• 10/16/2026 – OPKO Health was upgraded by Barrington Research from “market perform” to “outperform”. They now have a $2.25 price target on the stock.
• 9/28/2026 – OPKO Health was upgraded by Zacks Research from “hold” to “strong-buy”.

OPKO Health, Inc is a healthcare company focused on diagnostics and pharmaceuticals. Through its BioReference Laboratories business, the company provides clinical laboratory services, including routine testing, specialty diagnostics, genetic testing and oncology-related laboratory services. OPKO also develops diagnostic products, including the 4Kscore test, a blood test designed to help assess the risk of aggressive prostate cancer.

In pharmaceuticals, OPKO develops treatments for kidney disease, endocrine disorders and other conditions.